The DOI matches its Crossref record.
Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition
Abstract
As part of the ongoing Wisconsin Cystic Fibrosis (CF) Neonatal Screening Project, we had the unique opportunity to study the longitudinal relationship between Pseudomonas aeruginosa (Pa) acquisition and infection and developing lung disease in children with CF. The primary objective was to determine whether acquisition of Pa was associated with a measurable change in the progression of lung disease. Two outcome measures were used to study 56 patients who were diagnosed through newborn screening: 1) Wisconsin additive chest radiograph score (WCXR), based on the average of scores from a pulmonologist and a radiologist, and 2) the highest forced expired volume in 1 sec (FEV(1))/forced vital capacity (FVC) ratio. We used two measures of Pa acquisition: 1) time of first positive protocol-determined oropharyngeal (with cough) culture, and 2) the magnitude of antibody titer detected by ELISA assays, using as antigen a crude cell lysate, purified exotoxin A, or an elastase toxoid prepared from three Pa strains. Other predictor variables included age, pancreatic status, height-for age, and weight-for-age-percentiles. The best regression model for predicting changes in the WCXR included time to first positive culture and antibody titer for Pa elastase. Prior to Pa acquisition, WCXR worsened by 0.45 points/year (P > 0.25); after Pa acquisition, the rate of worsening increased significantly (P < 0.001) to 1.40 points/year. Each antibody titer level (log base 2) increased the score by 0.48 points (P < 0.001). The best regression model for predicting change in the FEV(1)/FVC included only time to first positive culture. Prior to Pa acquisition, the FEV(1)/FVC ratio declined by 1.29%/year; after Pa infection, the rate of decrease significantly accelerated to 1.81%/year (P = 0.001). Our data show that Pa acquisition is associated with declining pulmonary status in children with CF, and that this effect is probably gradual rather than precipitous. Because these patients were diagnosed and treated aggressively, our estimates of the effects of Pa acquisition may be conservative. We also conclude that the WCXR appears to be more sensitive than FEV(1)/FVC in detecting early changes in lung disease associated with CF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The hierarchy quorum sensing network in Pseudomonas aeruginosa
Lee, J., & Zhang, L. (2015) · Protein & Cell · doi:10.1007/s13238-014-0100-x · Cited by 1,346
O'Sullivan, B. P., & Freedman, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60327-5 · Cited by 1,320
Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium
Mesaros, N., Nordmann, P., Plésiat, P., Roussel-Delvallez, M., Van Eldere, J., Glupczynski, Y., Van Laethem, Y., Jacobs, F., Lebecque, P., Malfroot, A., et al. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01681.x · Cited by 585
Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis
Hauser, A. R., Jain, M., Bar-Meir, M., & McColley, S. A. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-10 · Cited by 411
Lung microbiota across age and disease stage in cystic fibrosis
Coburn, B., Wang, P. W., Diaz Caballero, J., Clark, S. T., Brahma, V., Donaldson, S., Zhang, Y., Surendra, A., Gong, Y., Elizabeth Tullis, D., et al. (2015) · Scientific Reports · doi:10.1038/srep10241 · Cited by 395
Infection Control in Cystic Fibrosis
Saiman, L., & Siegel, J. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.1.57-71.2004 · Cited by 324
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Langton Hewer, S. C., & Smyth, A. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004197.pub4 · Cited by 324
Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis
Gibson, R. L., Emerson, J., McNamara, S., Burns, J. L., Rosenfeld, M., Yunker, A., Hamblett, N., Accurso, F., Dovey, M., Hiatt, P., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-855oc · Cited by 318
Konstan, M. W., Flume, P. A., Kappler, M., Chiron, R., Higgins, M., Brockhaus, F., Zhang, J., Angyalosi, G., He, E., & Geller, D. E. (2011) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2010.10.003 · Cited by 314
Staphylococcus aureus Serves as an Iron Source for Pseudomonas aeruginosa during In Vivo Coculture
Mashburn, L. M., Jett, A. M., Akins, D. R., & Whiteley, M. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.2.554-566.2005 · Cited by 312
Early intervention and prevention of lung disease in cystic fibrosis: a European consensus
Döring, G., & Hoiby, N. (2004) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2004.03.008 · Cited by 304
Managing Cystic Fibrosis: Strategies That Increase Life Expectancy and Improve Quality of Life
Cohen-Cymberknoh, M., Shoseyov, D., & Kerem, E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201009-1478ci · Cited by 287
Heijerman, H., Westerman, E., Conway, S., & Touw, D. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2009.04.005 · Cited by 264
Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis
Parkins, M. D., Somayaji, R., & Waters, V. J. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-18 · Cited by 253
Coffey, M. J., Whitaker, V., Gentin, N., Junek, R., Shalhoub, C., Nightingale, S., Hilton, J., Wiley, V., Wilcken, B., Gaskin, K. J., et al. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.10.045 · Cited by 73
Metadata
- Authors
- Kosorok, M. R., Zeng, L., West, S. E. H., Rock, M. J., Splaingard, M. L., Laxova, A., Green, C. G., Collins, J., & Farrell, P. M.
- Venue
- Pediatric Pulmonology
- Publisher
- Wiley
- Published
- 2001-10
- Volume
- 32
- Issue
- 4
- Pages
- 277-287
- ISSN
- 1099-0496 (ISSN-L)
- 8755-6863
- OpenAlex
- W2171230591
- Cited by
- 400
- References
- 0
- FWCI
- 8.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.